305 results about "Diclofenac" patented technology

The invention relates to a 2-(2-(2, 6-dichlorophenyl amido) phenyl) methyl acetate, relative synthesis method and application, belonging to the technical field of chemical pharmacy, which comprises that adds acid into diclofenac salt to acidify the salt into diclofenac, reacts diclofenac with methanol, or adds acid into diclofenac salt to acidify the salt into diclofenac, to be reacted with chloracetyl chloride to obtain 2-(2-(2, 6-dichlorophenyl amido) phenyl) methyl acetate. The inventive drug has significant anti-inflammatory and analgesic effects.

The invention herein relates to a transdermal drug delivery systern for anti-Inflammatory analgesic. agent comprising diclofenac diethylammonium salt, wherein a backing film (1), a matrix layer (2) containing active ingredients, a release liner (3) which is removed before application onto the skin are laminated therein. Mome particularly, the invention herein relates to a transdermal drug delivery system for anti-inflammatory analgesic agent comprising diclofenac diethylammonum salt, wherein the transdermal penetration and adhesion of the patch to the body are enhanced by means of a matrix layer which comprises a diclofenac diethylammonum salt as active ingredient in addition to acrylic polymer as adhesive constituent, non-ionic surfacant as absorption enhancer, terpene and dissolution assistant, and the volatile and non-volatile constituents of the composition arc separately applied therein for significantly reducing the manufacturing time thereof.

The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.

Novel NSAID pharmaceutical compositions and methods for the treatment of skin disease and disorders such as actinic keratosis using same are disclosed.

The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.

The present invention provides a proprietary compositions and systems to modulate genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and prognosis, as well as the metabolism, efficacy and/or toxicity associated with specific vitamins, minerals, herbal supplements, homeopathic ingredients, and other ingredients for the purposes of customizing a subject's nutritional supplement formulation to optimize specific health outcomes. Specific to this invention the utilization of certain known polymorphic genes associated with Substance Use Disorder (SUD) are analyzed to target certain genetic anomalies that lead to a high risk and predisposition to SUD. The genotypic patterns are then utilized to provide certain nutritional customized solutions especially related to the attenuation of aberrant abuse of physician prescribed narcotic pain medication across all pain conditions. A priority GENOPROFILE is measured and directs the customization of a subsequent nutraceutical to act as a therapeutic modality. Specifically the treatment includes slow attenuation of the pain medication by incorporating orals (shakes, liquid beverages, pills, tablets, troche, ointments etc.), Intramuscular, Intravenous, intra-rectal and any form necessary to deliver a sufficient amount of an anti-craving and anti-stress nutraceutical. Moreover, the invention includes examples of novel analgesic ointments coupling Synaptamine and such analgesic and other anesthetic compounds including but not limited to Gabapentin, Ketamine, Baclofen, Ketoprofen, Amitriptyline, Lidocaine, Cyclobenzapine, Diclofenac, Menthol, Camphor and Capsaicin. The GENOPROFILE will be used to determine pain sensitivity Intolerance.

This invention relates to a stable parenteral aqueous solutions comprising either (a) diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or (b) an inclusion complex of diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or a mixture of (a) and (b), which are suitable for intramuscular and intravenous administration. The solutions contain diclofenac or diclofenac salt, cyclodextrin, and an antioxidant selected from monothioglycerol, or a combination of ethylene diamine tetra-acetic acid and N-acetyl-cysteine.

The present invention provides pharmaceutically acceptable salts having local anesthetic and anti-inflammatory activities. The preferred pharmaceutically acceptable salt is a diclofenac salt of lidocaine. Diclofenac is a non-steroidal anti-inflammatory drug (“NSAID”). Lidocaine is a local anesthetic. Other NSAID (except the salicylic acid derivatives of NSAID) can be used to replace diclofenac and/or other local anesthetics can be used to replace lidocaine. The pharmaceutically acceptable salts are crystalline compounds, which are distinctively different from either the NSAID alone or the local anesthetic alone, as indicated by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), High Performance Liquid Chromatography (HPLC) and Fourier-Transformed Infrared Spectroscopy (FTIR) analyses. These pharmaceutically acceptable salts are suitable for use in topical treatment or parenteral injection to treat patients with localized pain, including muscle pain, joint pain, pain associated with herpes infection, and wound pain (such as surgical wound, burn wound etc.).

The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.

The invention discloses a compound transdermal patch used for curing acute and chronic inflammatory pain. The patch comprises a compound penetrating agent and a pressure sensitive adhesive and is characterized by also comprising Xylocaine or hydrochloride thereof and sodium salt or sylvite of diclofenac. The transdermal patch contains the following components by weight percentages: 1-20 percent of Xylocaine or the hydrochloride thereof, 1-20 percent of the sodium salt or sylvite of diclofenac, 1-30 percent of compound penetrating agent and 40-49 percent of pressure sensitive adhesive. Aiming at overcoming the defects of the existing medicinal preparations in treatment and use, the invention provides a compound transdermal patch that is used for curing acute and chronic inflammatory pain, can act on local human body and quickly permeate, and is good in treatment effect, safe and convenient in use.

Methods, compositions and kits for treating a headache in a human patient are provided. The methods comprise intranasally administering to the patient a composition comprising a short-acting local anesthetic, a long-acting local anesthetic and a non-steroidal anti-inflammatory drug. A composition useful for practicing the methods of the disclosure is described which comprises a short-acting local anesthetic, a long-acting local anesthetic and a non-steroidal anti-inflammatory drug, wherein the composition is formulated for intranasal delivery. A kit comprising the composition and an intranasal applicator and a method of systemically delivering the composition to a human patient is also included in the disclosure. The headache-treating effectiveness of a local anesthetic in a Sphenopalatine Ganglion Block (SFGB) is significantly enhanced by coadministering diclofenac.

New pharmaceutical compositions for oral use containing diclofenac preferably together with alkali metal bicarbonates in amounts of from about 20 to about 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects; in particular, these formulations permit to obtain in human patients higher C_max of the active principle and shorter T_max together with a lower coefficient of variation.

New pharmaceutical compositions for oral use containing diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects; in particular, these formulations permit to obtain in human patients higher C_max of the active principle and shorter T_max together with a lower coefficient of variation.

The invention relates to the technical field of medicine, in particular to diclofenac sodium sustained release tablets and a preparation process thereof. The diclofenac sodium sustained release tablets provided by the invention comprise the following components in percentage by mass: 16.5 to 39.0 percent of diclofenac sodium, 10.0 to 35.5 percent of sustained release agent, 33.5 to 65.0 percent of filling agent, 2.01 to 8.0 percent of glidant, 0 to 2.5 percent of lubricating agent, and 0 to 8.0 percent of adhesive. According to the diclofenac sodium sustained release tablets and a whole-powder direct tabletting method thereof provided by the invention, by changing the components and the preparation method, the production process is simplified, the production cost is reduced, the production efficiency is improved, the yield is improved to 98.0 to 100 percent, granule condensation is avoided, the surface of the tablets is smooth, meanwhile, consumption of high-concentration alcohol is avoided, and the potential safety hazard in the production process is reduced.

The invention relates to a specific probe substrate composition of cytochrome P450 (CYP450) enzyme and an application of the specific probe substrate composition in subtype enzyme activity detection of the cytochrome P450 enzyme. The composition comprises at least two of phenacetin, coumarin, amfebutamone, dextromethorphan, diclofenac and testosterone. The characteristics of multi-ion channels can be simultaneously detected by the specific probe substrate composition and a liquid chromatography-mass spectrometry technology, and the inhibition conditions of six CYP450 enzymes are determined simultaneously, so that the experiment flux efficiency is greatly improved, and the experiment cost is reduced.

The invention belongs to the technical field of photocatalysis and discloses a carbon dot modified oxygen-doped carbon nitride photocatalyst as well as a preparation method and an application thereof.The method comprises steps as follows: citric acid and urea are added to ultrapure water and subjected to reaction at 170-190 DEG C after being ultrasonically dissolved, a mixed solution is cooled toroom temperature, centrifuged, dried and subjected to constant-volume treatment with the ultrapure water, and a CDs solution is obtained; semicarbazide hydrochloride is subjected to calcining reaction at 540-560 DEG C, cooled, ground and sieved, and O-C3N4 is obtained; O-C3N4 is added to a crucible, the ultrapure water and ethanol are added, then the CDs solution is added, after ultrasonic dissolving, water-bath heating and stirring are performed until the mixture is dry, the calcining reaction is performed at 280-320 DEG C, a product is cooled, ground and sieved, and the photocatalyst is obtained. With the adoption of a thermo polymerization method, the synthetic process is simple, repeatability is good, and basic conditions for large-scale production are provided; the CDs in the photocatalyst can convert long-wavelength light into short-wavelength light, the catalytic effect is improved, and diclofenac can be degraded under different light sources.

The present invention provides a topical formulation containing NSAID, particularly diclofenac. The topical formulation is particularly useful for alleviating pain/inflammation associated with infection caused by herpes virus, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV). Similar relief can be achieved where diclofenac is replaced with another non-steroidal anti-inflammatory drug (NSAID), which includes, without limitation, etodolac, ketorolac, bromfenac, diflunisal, ibuprofen, fenoprofen, ketoprofen, naproxen, suprofen, meclofenamate, mefenamic acid, piroxicam, meloxicam, indomethacin, sulindac, phenylbutazone, oxyphenbutazone, and tolmetin. The topical formulation is further characterized by its fast relief on pain and/or inflammation associated with infection caused by herpes virus, i.e., a complete relief in no more than seven (7) days after the application of the topical formulation on skins of patients.

The invention discloses a compound acetaminophen injection for livestock and its preparation method. the injection comprises acetaminophen 50-200, diclofenac sodium 10-50, polyethylene glycol-400 100-500, propylene glycol 100-500, and sodium bisulfite 10-30. the preparation method comprises (1) mixing polyethylene glycol-400 and propylene glycol, heating to 70-80deg.C, adding diclofenac sodium, stirring, adding acetaminophen, stirring; (2) heating water for injection to 30-40deg.C, adding sodium bisulfite, stirring; and (3) merging the solutions of steps 1 and 2, adjusting pH to 4.5-6.5 with hydrochloric acid or sodium hydroxide, and adding water for injection to 1000 to obtain the final product. The invention strengthen antipyretic and analgesic effects, is effective for treating pain and fever due to different kinds of inflammation, and can improve animal survival rate and increase animal body weight.

The freeze dried powder for injection containing diclofenac salt and lidocaine is prepared with Tween-80, pharmaceutically acceptable solution pH regulator, solution of diclofenac salt and lidocaine of pH 7.0 and in effective treating amount, and through freeze drying. The solution may contain other pharmaceutically acceptable supplementary material. The preparation of the present invention has stable performance, easy transportation, long storage period, and no bad reaction caused by alcohol and other organic solvent.

An active agent containing adhesive composition suitable for transdermal drug delivery having excellent water absorbability which comprises an effective amount of an active agent, an acrylate adhesive, a polyvinylpyrrolidone having a molecular weight of 1,000,000-5,000,000; a polyvinylpyrrolidone having a molecular weight of 2,000-50,000; a non-ionic surfactant; a terpene; and a dissolution assistant.

The invention relates to a method for removing diclofenac contained in sewage by utilizing a copper-iron heterogeneous fenton technology. The method comprises the following steps: adding bivalent copper salt, nanometer zero-valent iron and hydrogen peroxide to the sewage which contains the diclofenac under the condition that a pH value is 3-5, reacting for 3-12 minutes, oxygenizing to remove the diclofenac contained in the sewage, wherein the mass concentration of the diclofenac contained in the sewage is 1-50 milligrams/litre, the addition amount of the bivalent copper salt added to every litre of the sewage is 50-1000 milligrams, the addition amount of the nanometer zero-valent iron added to every litre of the sewage is 0.5-3.0 grams, and the addition amount of the hydrogen peroxide added to every litre of the sewage is 400-1000 milligrams. Compared with the prior art, the method disclosed by the invention has the advantages that the bivalent copper salt, the nanometer zero-valent iron and the hydrogen peroxide are added to waste water which contains the diclofenac and a bimetal system can promote the velocity of Fenton reaction because the electron affinity of Cu is relatively higher, thereby accelerating the reaction velocity; the method disclosed by the invention can achieve very good removal effect at normal temperature and pressure because the reaction temperature is unlimited and achieve high removal rate on the diclofenac without secondary pollution and is favorable to the recycling of the sewage.

The present invention provides injectable formulations of water-soluble salts of diclofenac in single doses of less than 2 ml, which cause significantly less pain at the site of injection and can be administered by intradeltoid route, in addition to intragluteal and slow intravenous route. More specifically the injectable preparations contain 75 mg to 100 mg of water-soluble salts of diclofenac, in about 1 ml injection solution without significantly raising the viscosity of the injection solution without the use surfactants. The formulations are adjusted to pH 6 to 10 containing up to 100 mg of diclofenac salt in a medium comprising of water, along with one or more co-solvent(s)/solubiliser(s), antioxidants, preservatives, buffers, alkali and stabilizers.